Which pharmaceutical company produces the generic version of Sotorasib?

Sotorasib is a drug that targets KRAS G12C mutations and is mainly used to treat patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutations. This drug has been launched in foreign markets. The original drug is produced by Amgen Company, and the price is relatively high, especially the European version and the Hong Kong version, which are usually priced at more than tens of thousands of yuan. Therefore, many patients face a large financial burden, especially in the case of long-term treatment.

However, as market demand increases, generic versions of sotorasibu have begun to appear in overseas markets. Taking Laos as an example, two companies, Lucius and Daxiong, have produced generic drugs of sotorasibu, and the price is much cheaper than the original drug. Recently, the price of generic drugs produced by these two companies in Laos has dropped significantly. A 120 mg*56 tablet of generic drug only costs more than 1,000 yuan, which is much lower than the price of the original drug. This price difference allows some patients with more limited financial conditions to reduce financial pressure by purchasing generic drugs.

The ingredients of generic drugs and original drugs in Laos are basically the same, and they are both drugs targeting the KRAS G12C mutation. Therefore, patients can expect similar efficacy and safety to the original drug when using it. However, since generic drugs may differ in quality and production standards, patients need to ensure that they are purchased through formal channels to ensure the quality and safety of the drugs. It is worth noting that when patients choose generic drugs, it is best to do so under the guidance of a doctor to ensure the effectiveness and safety of the treatment plan.
Although sotoracib is not yet available in China, it has become a viable option for patients to purchase original drugs or generic drugs through overseas channels. Because of the price difference, generic drugs offer many patients a more affordable treatment option. When purchasing, patients should obtain it through formal international drug platforms or overseas pharmacies and ensure that the drugs meet corresponding quality standards. During the treatment process, patients still need to monitor and adjust under the guidance of their doctor to achieve the best treatment effect.
Reference: https://www.lumakras.com/